Cholera.
- 1 January 1995
- journal article
- review article
- Vol. 8 (1) , 48-86
Abstract
Despite more than a century of study, cholera still presents challenges and surprises to us. Throughout most of the 20th century, cholera was caused by Vibrio cholerae of the O1 serogroup and the disease was largely confined to Asia and Africa. However, the last decade of the 20th century has witnessed two major developments in the history of this disease. In 1991, a massive outbreak of cholera started in South America, the one continent previously untouched by cholera in this century. In 1992, an apparently new pandemic caused by a previously unknown serogroup of V. cholerae (O139) began in India and Bangladesh. The O139 epidemic has been occurring in populations assumed to be largely immune to V. cholerae O1 and has rapidly spread to many countries including the United States. In this review, we discuss all aspects of cholera, including the clinical microbiology, epidemiology, pathogenesis, and clinical features of the disease. Special attention will be paid to the extraordinary advances that have been made in recent years in unravelling the molecular pathogenesis of this infection and in the development of new generations of vaccines to prevent it.This publication has 98 references indexed in Scilit:
- G proteinsPublished by Elsevier ,2003
- The second cholera toxin, Zot, and its plasmid‐encoded and phage‐encoded homologues constitute a group of putative ATPases with an altered purine NTP‐binding motifFEBS Letters, 1992
- Development and evaluation of a rapid, simple, sensitive, monoclonal antibody-based co-agglutination test for direct detection of Vibrio cholerae 01FEMS Microbiology Letters, 1992
- Onset and Duration of Protective Immunity in Challenged Volunteers after Vaccination with Live Oral Cholera Vaccine CVD l03-HgRThe Journal of Infectious Diseases, 1992
- TCP pilus biosynthesis in Vibrio cholera O1: gene sequence of tcpC encoding an outer membrane lipoproteinFEMS Microbiology Letters, 1992
- Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian childrenThe Lancet, 1992
- Safety and Immunogenicity of Different Immunization Regimens of CVD 103-HgR Live Oral Cholera Vaccine in Soldiers and Civilians in ThailandThe Journal of Infectious Diseases, 1992
- Environmental spread of Vibrio cholerae in PeruThe Lancet, 1991
- Cholera in Africa: lessons on transmission and control for Latin AmericaThe Lancet, 1991
- Purification of El Tor cholera enterotoxins and comparisons with classical toxinJournal of General Microbiology, 1990